Recruiting

AC 12L ECG

Sponsor:

AliveCor

Code:

NCT06271577

Conditions

Myocardial Infarction

Ischemia

Myocardial Ischemia

Heart Diseases

Cardiovascular Diseases

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

AliveCor 12-lead ECG

Study Details

Brief summary:

AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).

Recently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead ECG devices.

Conditions

Myocardial Infarction

Ischemia

Myocardial Ischemia

Heart Diseases

Cardiovascular Diseases

Study ID

NCT06271577

Start date

Mar 12, 2024

Status verified date

Apr, 2026

Completion date

Mar, 2027

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Male or female > 18 years of age.
  • Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.
  • Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.

Exclusion Criteria:

  • Inability or refusal of the patient and/or the patient's legally acceptable representative to provide written informed consent for any reason.
  • Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.

Study Design

Enrollment

1000 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: AliveCor 12-lead ECG

A single research-related procedure will be required (i.e., an AliveCor 12-lead ECG). Effort will be made to ensure that the performance of this procedure will not delay any treatment and/or diagnostic procedures that are part of usual or specialized care that the patient requires.

Interventions

AliveCor 12-lead ECG

The primary objective of this study is to determine if the AliveCor 12-lead Smartphone ECG is an acceptable substitute for a standard 12-lead ECG in the identification of STEMI and NSTEMI.

Primary outcome measure

  • Inter-rater variability for Standard 12-lead ECG readings [ Time Frame: 30 seconds ]
  • Inter-rater variability for AC 12L ECG readings [ Time Frame: 30 seconds ]
  • Number of standard 12-lead ECG readings requiring a consensus consultation [ Time Frame: 30 seconds ]
  • Number of AC 12L ECG readings requiring a consensus consultation [ Time Frame: 30 seconds ]
  • Sensitivity of AC 12L ECGs requiring consensus consultation, compared to standard 12-lead ECG requiring consensus consultation, for the diagnosis of STEMI [ Time Frame: 30 seconds ]
  • Specificity of AC 12L ECGs requiring consensus consultation, compared to standard 12-lead ECG requiring consensus consultation, for the diagnosis of STEMI [ Time Frame: 30 seconds ]
  • Positive predictive value of AC 12L ECGs requiring consensus consultation, compared to standard 12-lead ECG requiring consensus consultation, for the diagnosis of STEMI [ Time Frame: 30 seconds ]
  • Negative predictive power of the AC 12L ECGs requiring consensus consultation, compared to standard 12-lead ECG requiring consensus consultation, for the diagnosis of STEMI [ Time Frame: 30 seconds ]
  • Mean subjective correlation score for AC 12L ECGs in which the standard 12-lead ECG diagnosis is STEMI [ Time Frame: 30 seconds ]
  • Mean subjective correlation score for AC 12L ECGs in which the standard 12-lead ECG diagnosis is not STEMI [ Time Frame: 30 seconds ]
  • Mean summative ST-segment elevation, summative ST-segment depression and summative ST-segment deviation for AC 12L ECGs compared to standard 12-lead ECGs [ Time Frame: 30 seconds ]

Central Contacts and Locations

Central contacts

Locations

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Principal Investigator:

Gregory Barsness, MD

Intermountain Health

Recruiting

Murray, Utah, United States, 84107

Contacts

Principal Investigator:

Viet Le, PA-C

More Information

Sponsor

AliveCor

Last update posted

Apr 9, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by AliveCor on 2026-04-09.